Announcements
- Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024
- Interim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional Programs to Enter the Clinic in 2025, Update to MP0533 Program
- Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533’s Proposed Mechanism of Action
- Life Science Cares Launches in Switzerland
- Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting
- Molecular Partners Publishes Invitation to Annual General Meeting 2024
- Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023
- Molecular Partners Announces Dismissal of Class Action Lawsuit
- Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations
- Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting
More ▼
Key statistics
On Friday, Molecular Partners AG (6ML0:DUS) closed at 3.72, 24.83% above the 52 week low of 2.98 set on Apr 22, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.72 |
---|---|
High | 3.78 |
Low | 3.72 |
Bid | 3.58 |
Offer | 3.96 |
Previous close | 3.44 |
Average volume | 0.00 |
---|---|
Shares outstanding | 36.68m |
Free float | 33.17m |
P/E (TTM) | -- |
Market cap | 150.69m USD |
EPS (TTM) | -2.00 USD |
Data delayed at least 15 minutes, as of Jun 07 2024 18:30 BST.
More ▼